FCGR2B and malaria: The FCGR2B-p.Thr232Ile change (rs1050501) alters CD32B affinity for lipid rafts, thereby limiting its inhibitory function, and it seems to improve survival in malaria, while increasing susceptibility to SLE and childhood idiopathic thrombocytopenia (15, 24, 25).